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Abstract
Background: New Zealand has major ethnic disparities in breast cancer survival with Māori (indigenous
people) and Pacific women (immigrants or descended from immigrants from Pacific Islands) faring much
worse than other ethnic groups. This paper identified underlying factors and assessed their relative
contribution to this risk differential.
Methods: This study involved all women who were diagnosed with primary invasive breast cancer in two
health regions, covering about 40% of the national population, between January 2000 and June 2014. Māori
and Pacific patients were compared with other ethnic groups in terms of demographics, mode of diagnosis,
disease factors and treatment factors. Cox regression modelling was performed with stepwise adjustments,
and hazards of excess mortality from breast cancer for Māori and Pacific patients were assessed.
Results: Of the 13,657 patients who were included in this analysis, 1281 (9.4%) were Māori, and 897 (6.6%)
were Pacific women. Compared to other ethnic groups, they were younger, more likely to reside in
deprived neighbourhoods and to have co-morbidities, and less likely to be diagnosed through screening
and with early stage cancer, to be treated in a private care facility, to receive timely cancer treatment, and
to receive breast conserving surgery. They had a higher risk of excess mortality from breast cancer (age
and year of diagnosis adjusted hazard ratio: 1.76; 95% CI: 1.51–2.04 for Māori and 1.97; 95% CI: 1.67–2.32
for Pacific women), of which 75% and 99% respectively were explained by baseline differences. The most
important contributor was late stage at diagnosis. Other contributors included neighbourhood deprivation,
mode of diagnosis, type of health care facility where primary cancer treatment was undertaken and type of
loco-regional therapy.
Conclusions: Late diagnosis, deprivation and differential access to and quality of cancer care services were
the key contributors to ethnic disparities in breast cancer survival in New Zealand. Our findings underscore
the need for a greater equity focus along the breast cancer care pathway, with an emphasis on improving
access to early diagnosis for Māori and Pacific women.
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Background
Breast cancer is the most common cancer for women
worldwide. In New Zealand, breast cancer accounted for
almost 30% of all new cancer cases and 14% of all cancer
deaths in 2012 [1, 2]. While survival from breast cancer
has improved over time, net survival in New Zealand is
inferior to some other developed nations [3], including
its neighbour Australia [4]. Of great concern is large sur-
vival inequities that exist within the country, with the
poorest outcomes experienced by Māori (indigenous
people, constituting 14% of New Zealand women) and
Pacific women (immigrants or descended from immi-
grants from Pacific Islands, constituting 7% of New Zea-
land women) [2].
Causes of ethnic disparities in cancer survival are com-
plex and likely to include a range of factors related to
patient demographics, tumour biology, and inequities in
access, timeliness and quality of care along the cancer
diagnosis and treatment pathway. Compared with New
Zealand European women, Māori and Pacific women
have a younger age distribution [5], and are more likely
to live in deprived areas [6], to have comorbid condi-
tions [7], to experience unmet need for health care [8]
and to receive poorer quality health care [9].
New Zealand has a publicly funded national health
system that provides free secondary health care to all
residents but primary health care is only partially
government-subsidised. Previous research found that,
compared with their New Zealand European counter-
parts, Māori and Pacific women were more likely to be
diagnosed with advanced breast cancer [10], along with
being less likely to be diagnosed through screening, [11]
and less likely to receive timely and optimal cancer treat-
ment [12–15]. Although differences in tumour biological
factors have been postulated as being an important cause
of ethnic inequities in breast cancer survival, the
evidence to support that hypothesis is weak [16–19]. In
previous analyses based on a regional breast cancer
register involving 2679 patients, late stage at diagnosis
contributed most to survival disparities between Māori
and New Zealand European women [20], and differences
in biological factors had minimal impact [21]. That
study, however, did not investigate disparities in Pacific
women. In an earlier study involving 2968 patients iden-
tified from the New Zealand Cancer Registry,
deprivation and markers of timely access to care
(tumour extent and size at presentation) accounted for
most of the ethnic disparities in breast cancer survival
[22]. The study, however, did not assess the contribution
of treatment factors in the analyses.
This study involved 13,657 patients identified from the
two regional breast cancer registries and assessed the
relative contribution of demographic, disease and treat-
ment factors in explaining survival disparities for Māori,
Pacific and non-Māori non-Pacific patients who were di-
agnosed with primary breast cancer.
Methods
Study population
This study involved all women diagnosed with primary
invasive breast cancer between January 2000 and June
2014 in the four District Health Board regions (Auck-
land, Counties Manukau, Waitemata and Waikato),
where about two-fifths of the country’s population res-
ide. These combined regions have similar breast cancer
incidence and mortality rates to national figures [1].
Data sources
Participants were identified from the Auckland and
Waikato Breast Cancer Registers which are prospectively
maintained population-based databases. From 2000
onward, the registers captured almost all newly
Fig. 1 A simplified causal diagram depicting the role of mediating factors
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Table 1 Baseline characteristics by ethnicity
Characteristics Māori (N = 1283) Pacific (N = 898) Non-Māori Non-
Pacific (N = 11,489)
p-value
Crude Adjusted Crude Adjusted Crude Adjusted Crude Adjusted












1–2 % 5.0 4.7 4.5 4.1 23.4 24.2 <0.0001 <0.0001
3–4 % 8.3 8.7 5.1 6.4 18.4 20.4
5–6 % 15.0 16.2 10.1 12.8 21.0 23.0
7–8 % 23.7 25.3 20.5 23.3 17.8 19.0
9–10 % 44.4 45.1 52.3 53.5 13.2 13.5
Missing/unknown % 3.7 7.5 6.2
Area of residence
Urban % 73.0 78.3 85.4 94.9 78.3 86.4 <0.0001 <0.0001
Rural % 20.1 21.7 2.7 5.1 12.0 13.6
Missing/unknown % 6.9 11.9 9.7
Register
Auckland % 63.6 62.7 93.5 92.5 77.7 77.9 <0.0001 <0.0001a
Waikato % 36.4 37.4 6.5 7.5 22.3 22.1
Screen-detected % 36.1 35.0 31.0 29.9 39.3 39.5 <0.0001 <0.0001a
<45 years old % 2.4 2.8 0.5 0.9 8.2 8.1 <0.0001 <0.0001a
45-69 years old % 49.7 49.2 47.0 47.2 54.9 55.0 <0.0001 <0.0001a
70+ years old % 9.5 5.2 7.3 3.6 15.5 15.9 0.01 <0.0001a
Stage at diagnosis
I % 34.8 34.9 25.6 25.7 43.6 43.6 <0.0001 <0.0001a
II % 39.8 40.3 40.5 41.0 38.4 38.4
III % 17.9 17.3 23.2 22.4 13.9 14.1
IV % 7.3 7.55 10.6 10.9 3.9 3.9
Missing/unknown % 0.1 0.1 0.2
Grade
I % 20.6 21.8 15.7 17.2 24.1 24.7 <0.0001 <0.0001a
II % 46.7 51.1 42.8 47.9 44.0 46.9
III % 26.9 27.1 35.0 34.9 26.8 28.4
Missing/unknown % 5.8 6.6 5.1
Histology
Ductal % 83.6 82.8 83.9 83.0 78.8 79.5 <0.0001 0.2a
Lobular % 7.8 8.9 6.5 7.9 12.1 12.5
Other % 7.9 8.3 8.6 9.1 8.0 8.0
Missing/unknown % 0.8 1.1 1.1
Hormone receptor status
ER+/PR+ % 67.7 67.8 65.6 65.8 63.2 63.9 <0.0001 0.03a
ER+/PR- % 11.9 14.0 8.1 11.5 14.8 15.9
ER−/PR+ % 1.4 2.3 1.3 2.5 1.4 2.2
Tin Tin et al. BMC Cancer  (2018) 18:58 Page 3 of 10
diagnosed breast cancer cases in the respective district
health board regions. Both databases contain much more
comprehensive and accurate information than national
data sources [23–25].
Using the National Health Index (NHI) number, a
unique identifier assigned to every person who uses
health and disability support services in New Zealand,
the registers are regularly linked to the National Cancer
Registry and Mortality Collection. The New Zealand
Cancer Registry contains information about all malig-
nant tumours first diagnosed in New Zealand, except
basal cell and squamous cell tumours of the skin [26].
The Mortality Collection contains information about all
deaths registered in the country [27]. In order to obtain
information on comorbidities, Breast Cancer Registry
data were also linked to the National Minimum Dataset
which contains information about all day patients and
inpatients discharged from all public hospitals and over
90% of private hospitals in New Zealand [28].
Variables of interest
The exposure of interest in this analysis was ethnicity.
Patients were classified as Māori, Pacific and non-Māori
non-Pacific based on ethnicity recorded in the breast
cancer registers. The Waikato Registry collects self-
identified ethnicity whereas ethnicity data in the
Table 1 Baseline characteristics by ethnicity (Continued)
Characteristics Māori (N = 1283) Pacific (N = 898) Non-Māori Non-
Pacific (N = 11,489)
p-value
Crude Adjusted Crude Adjusted Crude Adjusted Crude Adjusted
ER−/PR- % 16.3 15.9 20.7 20.2 17.8 18.1
Missing/unknown % 2.7 4.2 2.8
HER-2
Positive % 16.1 16.2 20.8 21.3 11.8 13.6 <0.0001 <0.0001a
Equivocal % 1.8 13.6 1.0 15.3 1.7 13.2
Negative % 65.6 70.3 56.4 63.4 64.0 73.3
Missing/unknown % 16.5 21.8 22.5
C3 index scores
0 % 69.8 65.6 72.4 67.5 79.5 80.3 <0.0001 <0.0001a
1 % 9.6 10.3 8.4 9.2 7.9 7.7
2 % 8.6 24.1 7.8 23.3 5.3 11.9
Treatment facility type
Public % 83.8 86.6 84.2 87.3 53.2 52.6 <0.0001 <0.0001a
Private % 16.2 13.4 15.8 12.7 46.8 47.4














Breast conserving surgery + radiotherapy % 37.4 38.2 27.2 32.1 42.7 42.2 <0.0001 <0.0001c
Breast conserving surgery alone % 7.4 8.1 6.4 8.0 9.1 8.9
Mastectomy + radiotherapy % 20.8 17.6 23.5 16.4 16.4 17.3
Mastectomy alone % 25.9 27.7 28.6 31.1 25.7 25.3




% 27.5 20.9 26.8 16.8 22.3 23.8 <0.0001 <0.0001c
Chemotherapy alone % 10.9 10.7 9.0 6.3 9.6 9.9
Hormonal/biological treatment alone % 39.7 42.6 38.9 44.8 40.6 39.8
None % 21.9 25.92 25.3 32.1 27.5 26.5
aMissing data imputed and proportion adjusted for age and year of diagnosis
bRestricted to 13,314 patients who received cancer treatment during follow-up
cMissing data imputed and proportion adjusted for age, year of diagnosis and disease factors (stage at diagnosis, grade, histological type and ER/PR status)
Tin Tin et al. BMC Cancer  (2018) 18:58 Page 4 of 10
Auckland registry is based on that linked to the National
Health Index. Patients with more than one recorded eth-
nicity were allocated to a single ethnic group in order of
priority: Māori, Pacific, Asian and European/Other [29].
The primary study outcome was breast cancer specific
mortality. Categorisation of death due to breast cancer
was based on medical records and death certificates. In-
formation on cause of death was ascertained by referring
to original documents and cross-referencing with other
national databases.
Other variables for this analysis were selected based
on their likely confounding or mediating effect on the
exposure-outcome association, and these include: pa-
tients’ demographics such as age and health domicile
code, year of cancer diagnosis, mode of diagnosis (screen
or symptomatic), tumour characteristics such as stage at
diagnosis (Tumour, Node and Metastasis (TNM) sys-
tem), grade, histological type and hormone receptor sta-
tus, heath care facility type where primary cancer
treatment was undertaken (private or public), time to
first treatment, and type of treatment such as loco-
regional therapy (i.e., surgery and radiotherapy), chemo-
therapy and hormonal therapy.
The health domicile codes represent patients’ usual
residential address and were categorised as urban (main
urban, satellite urban and rural with high urban influ-
ence) and rural areas (others) based on Statistics New
Zealand’s Urban/Rural Profile [30]. To assess the degree
Table 2 Hazards of death from breast cancer in Māori and Pacific women in comparison with non-Māori non-Pacific women
Models Additional variables in the model Hazard ratios (95% CI) % attenuationa (95% CIb)
Māori vs. non-Māori non-Pacific
1. Age and year of diagnosis adjusted 1.76 (1.51, 2.04)
2. Model 1 + Tumour biology Grade 1.73 (1.49, 2.01)
Histology 1.73 (1.49, 2.02)
Hormone receptor status 1.82 (1.56, 2.13) −6.5 (−18.3, 2.3)
3. Model 2 + Area of residence NZDep2006 1.70 (1.45, 1.99)
Rurality 1.69 (1.44, 1.98)
Registries 1.67 (1.42, 1.96) 9.2 (−3.7, 22.6)
4. Model 3 + Mode of diagnosis Screen detected 1.58 (1.35, 1.85) 18.7 (5.7, 33.7)
5. Model 4 + Tumour stage at diagnosis Stage 1.26 (1.07, 1.49) 58.8 (33.9, 83.1)
6. Model 5 + Comorbidity C3 index scores 1.27 (1.07, 1.49) 58.2 (32.6, 82.0)
7. Model 6 + Treatment facility type Public vs. private 1.21 (1.02, 1.43) 66.5 (44.0, 97.6)
8. Model 7 + Treatment factors Time to first treatment 1.21 (1.02, 1.43)
Loco-regional therapy 1.14 (0.95, 1.36)
Systemic therapy 1.15 (0.97, 1.37) 74.9 (51.2, 110.0)
Pacific vs. non-Māori non-Pacific
1. Age and year of diagnosis adjusted 1.97 (1.67, 2.32)
2. Model 1 + Tumour biology Grade 1.78 (1.50, 2.10)
Histology 1.78 (1.50, 2.11) 8.9 (−0.6, 18.2)
Hormone receptor status 1.85 (1.56, 2.20)
3. Model 2 + Area of residence NZDep2006 1.70 (1.42, 2.03)
Rurality 1.71 (1.43, 2.05)
Registries 1.78 (1.48, 2.13) 15.0 (0.2, 30.2)
4. Model 3 + Mode of diagnosis Screen detected 1.66 (1.38, 1.99) 25.0 (10.4, 42.1)
5. Model 4 + Tumour stage at diagnosis Stage 1.19 (0.98, 1.44) 74.3 (55.8, 106.8)
6. Model 5 + Comorbidity C3 index scores 1.19 (0.98, 1.44) 74.5 (55.8, 106.8)
7. Model 6 + Treatment facility type Public vs. private 1.11 (0.92, 1.35) 84.0 (62.9, 117.6)
8. Model 7 + Treatment factors Time to first treatment 1.12 (0.92, 1.36)
Loco-regional therapy 1.04 (0.85, 1.27)
Systemic therapy 1.01 (0.82, 1.23) 98.9 (74.1, 137.6)
a% attenuation compared with Model 1
b95% bootstrap confidence interval
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of neighbourhood deprivation, the domicile codes were
also mapped on to the 2006 New Zealand Deprivation
Index (NZDep) with decile ten the most deprived and
decile one the least [31]. Patients’ comorbidity was mea-
sured using a C3 index score which is a cancer-specific
index of comorbidity based on the presence of 42
chronic conditions recorded in the National Minimum
Dataset for a period of 5 years prior to the diagnosis of
cancer [32]. Each condition was weighed to its impact
on one-year non-cancer mortality in a cancer cohort,
and the weights were then summed to get a final comor-
bidity score.
Analyses
Analyses involved 13,657 women diagnosed with inva-
sive breast cancer, and excluded 2342 patients with stage
0 or in-situ cancer. Baseline data were presented as
means with standard deviations and medians with inter-
quartile ranges for continuous variables and percentages
for categorical variables. Missing values were computed
using multiple imputation with ten complete datasets
created by the Markov chain Monte Carlo method [33],
incorporating all baseline co-variables and survival out-
comes. Differences in baseline characteristics for Māori,
Pacific and non-Māori non-Pacific women were assessed
using a two-sample T-test (for continuous variables) and
Chi-squared test (for categorical variables) and adjusted
for age and the year of diagnosis using PROC MIXED
which fits a variety of mixed linear models to the data.
Differences in the time to the first treatment and types
of cancer treatment received were also adjusted for stage
at diagnosis, grade, histological type and hormone recep-
tor status.
Cumulative incidences for breast cancer specific mor-
tality were computed considering death from other
causes as the first event as a competing risk. Cox pro-
portional hazards regression modelling was performed
with death from breast cancer as the failure variable, and
death from another cause, or if alive, date of last follow-
up, as censored observations. Hazard ratios (HR) were
adjusted for age and year of diagnosis and then sequen-
tially adjusted for seven domains of co-variables: tumour
biological factors, area of residence, mode of presenta-
tion, stage at diagnosis, comorbidity index, treatment fa-
cility type and treatment factors (Figure 1). When the
continuous variables (age, time to first treatment and C3
index score) were added to the model, restricted cubic
splines were used with knots at the 5th, 50th, and 95th
percentiles [34]. HER-2 status was excluded as about
one-third of the records had missing values.
The mediating role of each domain was determined by
the percentage reduction in the β coefficient after inclu-
sion of each domain in the model using the approach
described previously [35]: 100 × (βcrude-βadjusted)/βcrude.
The 95% confidence intervals relating to each percentage
attenuation were estimated using a nonparametric boot-
strapping method with 2000 re-samplings (with replace-
ment). Subgroup analyses were undertaken by stage at
diagnosis (I and II vs. III and IV) and by mode of diag-
nosis (screen-detected vs. symptomatic). Sensitivity ana-
lyses were performed by restricting the sample to
patients who were diagnosed from 2006 onward to as-
sess the contribution of HER2, and by using total mor-
tality (deaths from any cause) as the outcome variable.
All analyses were performed using SAS (release 9.4, SAS
Institute Inc., Cary, North Carolina).
Results
Of the 13,657 women included in the analysis, 1281
(9.4%) were Māori, and 897 (6.6%) were Pacific women
(Table 1). Of the 11,479 (84.0%) non-Māori non-Pacific
group, 9679 (84.3%) were New Zealand European, 152
(1.3%) were other European and 1051 (9.2%) were Asian.
Compared to the non-Māori non-Pacific group, Māori
and Pacific patients were younger, and more likely to
reside in deprived neighbourhoods. Māori women were
more likely to reside in rural areas and the Waikato re-
gion (compared to Auckland) but the opposite was true
for Pacific women.
Compared with the non-Māori non-Pacific group,
Māori and Pacific women were less likely to be diag-
nosed through screening and with stage 1 and grade 1
cancer and more likely to have ductal cancer compared
to other ethnic groups. Māori women were more likely
to be oestrogen and progesterone receptor positive. Both
Māori and Pacific women were more likely to have co-
morbidities. They were less likely to be treated in a pri-
vate care facility, had a significantly longer time to first
treatment after diagnosis, and were less likely to receive
breast conserving surgery even after adjusting for stage
Fig. 2 Cumulative breast cancer specific mortality by ethnicity
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at diagnosis. Pacific patients were also less likely to re-
ceive chemotherapy.
During a median follow-up of 4.2 years, Māori women
had a significantly higher risk of mortality from breast
cancer than non-Māori non-Pacific women (age and
year of diagnosis adjusted HR 1.76; 95% CI: 1.51, 2.04)
(Fig. 2 and Table 2). Adjustments for residential factors,
mode of diagnosis, disease factors, C3 index score, treat-
ment facility type and treatment factors resulted in a
75% reduction in the HR. In particular, neighbourhood
deprivation, mode of presentation, stage at diagnosis,
and type of loco-regional therapy contributed most to
the risk differential between Māori and non-Māori non-
Pacific patients. After adjustment for all factors, the risk
of mortality was still 15% higher in Māori patients (HR
1.15; 0.97–1.37).
Pacific women had a significantly higher risk of mor-
tality from breast cancer than non-Māori non-Pacific
women (age and year of diagnosis adjusted HR 1.97; 95%
CI: 1.67, 2.32) (Fig. 2 and Table 2). Factors included in
the fully adjusted model reduced the HR to 1.01 (95%
CI: 0.82, 1.23). Tumour grade, neighbourhood
deprivation, mode of presentation, stage at diagnosis,
and type of loco-regional therapy contributed most to
the risk difference.
In subgroup analyses, the associations were similar in
early vs. advanced breast cancer (Additional file 1: Table
S1) but were weaker in women who were diagnosed
through screening (Additional file 1: Table S2). In sensi-
tivity analyses restricted to patients who were diagnosed
from 2006 onward, ethnic differences in HER2 status
contributed modestly to survival disparities in both
Māori and Pacific women (Additional file 1: Table S3).
When total mortality was used as the failure variable,
similar but stronger associations were observed
(Additional file 1: Table S4). The higher C3 index score
also contributed to ethnic disparities in overall survival.
Discussion
Main findings
This paper confirmed that survival disparities exist for
both Māori and Pacific women in the New Zealand con-
text. Our work shows that there are differences between
Māori and Pacific and non-Māori non-Pacific women
groups in terms of residential area, mode of presenta-
tion, disease factors, comorbidity index, treatment fac-
tors and cancer care facility type. These differences
explained approximately 75% and 99% respectively of
the survival disparities between Māori and Pacific and
non-Māori non-Pacific women. The most important
contributor was late stage at diagnosis. Other contribu-
tors included neighbourhood deprivation, mode of pres-
entation, treatment facility type and type of loco-
regional therapy. Tumour grade also contributed to the
survival differential in Pacific women.
Interpretations
Māori and Pacific women were almost twice as likely to
die from breast cancer as non-Māori non-Pacific
women. This is consistent with the findings from previ-
ous New Zealand research [19, 20, 22, 36–38]. The find-
ings also contribute to a growing literature on ethnic/
racial disparities in breast cancer incidence and out-
comes internationally [39–42].
Such disparities are likely to be due to social,
biological and health system determinants of poor
outcomes [42]. Consistent with previous research in
New Zealand and elsewhere [20, 43], stage at diagno-
sis accounted for a substantial proportion of the sur-
vival differential in Māori and Pacific women. The
high prevalence of late diagnosis in both ethnic
groups could be partly explained by unequal screen-
ing coverage. New Zealand has a publicly funded na-
tional breast cancer mammography screening
program for asymptomatic women aged 50 to
64 years since 1998. The program was extended to
include women aged 45 to 49 years and 65 to
69 years in 2004. While total population screening
coverage has improved over time and met the target
of 70%, coverage for Māori women remains relatively
low (65% nationally and 60% and 59% respectively in
Auckland and Waikato) [44]. The national coverage
for Pacific women has exceeded the target (72%) but
the coverage is still low in some regions including
the Waikato at 63%. We found that Pacific women
in the screening age group were least likely to be di-
agnosed through screening (47% in Pacific, 50% in
Māori and 55% in non-Māori non-Pacific women).
Other factors that could contribute to late diagnosis
include greater barriers related to access to primary
care practices and practitioners, low health literacy,
low socioeconomic status and psychosocial factors
[45–48]. These are worthy of further investigation
particularly because the differential stage distribution
was also a key contributor to survival disparities in
symptomatic patients.
In New Zealand, socioeconomic position has been re-
ported to be an important determinant of health and a
mediator in the association between ethnicity and health
[49]. In this study, about half of Māori and Pacific
women resided in the most deprived neighbourhoods
(cf. 13% of non-Māori non-Pacific women). While
NZDep2006 measures area-level deprivation and may
not reflect an individual’s actual socioeconomic status, it
may be regarded as a marker of health care access. In a
recent population-based case-control study involving pa-
tients with breast cancer, Māori and Pacific women were
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more likely to report “cost” as a barrier to accessing
cancer care [50]. Many studies have also linked aspects
of socioeconomic deprivation with poorer cancer
survival through late diagnosis and differential treatment
[51, 52].
Māori and Pacific women (16% each) were signifi-
cantly less likely to access private care for their primary
treatment for breast cancer than non-Māori non-Pacific
women (47%). In New Zealand, alongside the publicly
funded national health system, the private system pro-
vides a range of services including elective treatments
and general surgical procedures which are mostly funded
by private health insurance. Our previous research has
linked private care with earlier diagnoses, better treat-
ments and higher survival from breast cancer [53]. In
this analysis, we found that differential access to private
care accounted for 8% and 10% respectively of survival
disparities in Māori and Pacific women.
In addition to experiencing diagnostic delays, Māori
and Pacific women had a significantly longer time to the
first treatment for breast cancer as reported previously
[54]; however, treatment delays following diagnosis con-
tributed minimally to the survival inequities between
ethnic groups. This throws into question, the usefulness
of the current New Zealand Ministry of Health “Faster
Cancer Treatment (FCT) Programme” for rectifying the
disparities in mortality we have shown. The FCT
programme aims to reduce waiting time for appoint-
ments, tests and treatment and sets a 62-day cancer
treatment target [55], and was adopted from the very
similar UK National Health Service programme. Our
analysis shows that it is the delay to the initial diagnosis
rather than delay to the start of treatment following
diagnosis that has contributed to the poorer outcome in
Māori and Pacific women. This indicates that more ef-
fort is required to improve early diagnosis of breast can-
cer for Māori and Pacific women. A priority must be to
increasing access to the National Screening Programme
for these women. Other possible actions include enhan-
cing access to primary care for Māori and Pacific women
with breast lumps, improving transition between pri-
mary and secondary care, raising awareness of the dis-
ease and emphasising the importance of early diagnosis.
We found that the type of loco-regional therapy also
contributed to ethnic disparities. Similar to what has
been observed in the US black vs. white populations
[56], Māori and Pacific women were less likely to receive
primary surgery and even when they did, they were less
likely to receive breast conserving surgery and radiother-
apy. Our analysis accounted for stage at diagnosis and
biological factors, so this does not reflect a higher preva-
lence of advanced cancer in Māori and Pacific women.
Another possible explanation is the fact that Māori and
Pacific women are more likely to be treated in the public
sector where the rate of primary surgery and radiother-
apy appears to be lower [53, 57, 58].
Strengths and limitations
This study used data from the two prospectively main-
tained population-based databases which contain com-
prehensive and near complete information about
patients diagnosed with primary breast cancer. Linkage
to national databases enabled us to ascertain information
on cause of death and to obtain information on comor-
bidities. However, potential misclassification of cancer-
specific deaths may still occur and may reduce observed
differences to a small extent. Information on ethnicity
recorded in the Auckland registry may not be accurate
as it is based on that linked to the National Health
Index. Comparisons between such data and census data
have shown undercounting of Māori by 15% and of Pa-
cific people by 10% [59]. This may move the observed
risk estimates toward the null, but in mediation analyses,
misclassification of the mediating variables is more im-
portant than that of the exposure and may underesti-
mate the % attenuation presented in this paper [60]. As
a considerable number of patients had missing data on
HER-2 status - most of whom were diagnosed prior to
2006 when HER-2 testing was not routine in New Zea-
land, we excluded HER-2 status from the analyses. The
contribution of HER2 was minimal in sensitivity analyses
restricted to patients who were diagnosed from 2006 on-
ward. It was not possible to assess the impact of some
important factors such as body mass index and smoking,
as relevant data were not recorded in the databases.
Conclusions
Māori and Pacific women had a higher risk of mortality
from breast cancer compared to other ethnic groups.
This was largely contributed by late stage at diagnosis
and also by important differences in neighbourhood
deprivation, mode of diagnosis, treatment facility type
and type of loco-regional therapy. Our findings under-
score the need for a greater equity focus along the breast
cancer care pathway in New Zealand, with an emphasis
on improving access to early diagnosis for Māori and Pa-
cific women. This may result in greater impact on im-
proving outcomes for women than just focusing on
faster treatment once diagnosed.
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